Investigational / not FDA-approved

Prostamax

KEDP tetrapeptide — thin Khavinson chromatin set; ≠ Vesugen ≠ Pinealon ≠ Epitalon.

Editorial review:

What evidence says

Evidence snapshot

This drawer marks papers. It is not a plan, a dose, or a source. A paper is a bounded report. It is not a protocol. Grades name the object. They are not a safety rating.

Identity lock. Prostamax is the synthetic tetrapeptide Lys-Glu-Asp-Pro (KEDP). PubChem CID 9848296; formula C20H33N5O9 / MW 487.5; CAS 473578-47-1. Khavinson-line “prostate bioregulator” peptide in chromatin / organotypic-culture literature. Prostamax ≠ Vesugen (KED); ≠ Pinealon (EDR); ≠ Epitalon (AEDG). This drawer marks papers. It is not use advice.

Bottom line

PubMed set is thin: lymphocyte heterochromatin / microcalorimetry papers, organotypic tissue-culture “tissue-specific” claims, and aging chromatin deheterochromatinization reports. No modern Phase 3 prostate-disease package is assumed. Refuse prostate-wellness glow.

Papers

PMID 15612551 — Meskhi 2004

Tested: influence of peptide bioregulator Prostamax on heterochromatin of human lymphocytes in situ.

Does not show: a clinical prostate-cancer or BPH outcome trial.

PMID 15085253 — Khavinson 2004

Tested: effects of short peptides on lymphocyte chromatin in senile subjects (includes Prostamax-class short peptides).

Does not show: disease-modifying prostate indication.

PMID 19359734 — Kiladze 2009

Tested: microcalorimetric study of human blood lymphocyte culture in presence of copper, cadmium, and Prostamax.

Does not show: clinical efficacy.

PMID 23221144 — Dzhokhadze 2012

Tested: deheterochromatinization of chromatin in old age induced by oligopeptide bioregulator (Lys-Glu-Asp-Pro).

Does not show: modern confirmatory RCT.

PMID 17152728 — Zakutsky 2006

Tested: tissue-specific effect of synthetic peptide bioregulators in organotypic tissue culture in young and old rats.

Does not show: human prostate outcomes.

PMID 28948547 — Khavinson 2017

Tested: peptides (epigenetic regulators) in structure of rodents with long vs short lifespan (program context).

Does not show: Prostamax lifespan extension in humans.

What is not established

Human clinical efficacy for prostate disease. Equivalence to Vesugen or other Khavinson short peptides. Anti-aging claims. This drawer does not provide use advice, schedules, or sourcing.

Selected sources

15612551 15085253 19359734 23221144 17152728 28948547

What people discuss

Reported experiences

Reported topics are not established benefits.

Watch for

Risks and unknowns

Context matters. Approval of one medicine, formulation, or use does not establish approval of products sold online or other uses. This page is educational and does not provide dosing or treatment advice.

Member discussion

Compare experiences with care.

Before posting: Describe firsthand observations and uncertainty. Do not prescribe, arrange transactions, or post private health information.

◎Verified members

Join the discussion

Verified members can contribute to compound conversations.

No approved member reports yet. Thoughtful first contributions are welcome.